SlideShare una empresa de Scribd logo
1 de 46
Dengue infection
  ReviseD Who
 guiDelines 2009
Dengue viral infection
● The most rapidly spreading mosquito-borne viral
  disease in the world
● Dengue virus :
  4 serotypes : DEN1, DEN2,DEN3, and DEN4
  Family Flaviviridae
  Genus Flavivirus
  Single stranded RNA virus
● “Asian” genotypes of DEN-2 and DEN-3 :
  frequently associated with severe disease
  accompanying secondary dengue infections
Dengue with who guidelines
Average annual number of DF and DHF cases reported to WHO, and of countries reporting dengue,
1955–2007
Dengue Virus Infection
● Immunity : long lasting in same serotype, partial and
  transient to other serotypes
● Primary infection, secondary infection
● Greater risk of serious symptoms in secondary
  infection
• Plasma leakage distinguishes dengue fever from
  dengue hemorrhagic fever
• Plasma leakage,hemoconcentration and abnormalities
  in homeostasis characterize severe dengue
Dengue Virus Infection:
            Clinical Syndromes
● Undifferentiated fever
● Dengue fever: fever, headache, muscle pain,
  nausea/vomiting, rash
● DHF
● DSS



                                                Gr I, II
                         Plasma leakage

                                                Gr III, IV
Definition of Dengue Hemorrhagic
                Fever
             4 necessary criteria:
• Fever, or recent history of acute fever
• Hemorrhagic manifestations
● Low platelet count (100,000/mm3 or less)
● Objective evidence of “leaky capillaries”
    elevated hematocrit (20% or more over baseline)
    pleural or other effusions
    Fall in hematocrit >20% after I.V Fluids
Definition of Dengue Shock Syndrone


4 criteria for DHF
● Evidence of circulatory failure manifested indirectly
  by all of the following:
    Rapid and weak pulse
    Narrow pulse pressure (< 20 mm Hg) OR hypotension
     for age
    Cold, clammy skin and altered mental status
● Frank shock is direct evidence of circulatory failure
WHO classification

● Undifferentiated fever
● Dengue fever (DF)
● Dengue haemorrhagic fever (DHF)
  4 severity grades
  grades III and IV : dengue shock syndrome (DSS)
● Currently the classification into DF/DHF/DSS
  continues to be widely used
WHO classification
● patients with non-severe dengue
  patients with warning signs
  patients without warning signs
● “dengue is one disease entity with different clinical
  presentations and often with unpredictable clinical
  evolution and outcome”
Dengue with who guidelines
Vectors

● Aedes aegypti




                Stegomyia aegypti
             (formerly Aedes aegypti)
Dengue
● incubation period of 4-10 days
● wide spectrum of illness (most, asymptomatic or
  subclinical)
● Primary infection : induce lifelong protective
  immunity to the infecting serotype
● Individuals suffering an infection are protected
  from clinical illness with a different serotype
  within 2-3 months of the primary infection
● no long-term cross-protective immunity
Risk factors (determine the severity of disease
            and secondary infection)
● Age
● Ethnicity
● Possibly chronic diseases (bronchial asthma, sickle
  cell anemia and DM)
● Young children (less able to compensate for capillary
  leakage and are consequently at greater risk of
  dengue shock)
● Secondary heterotypic infection as risk factor for
  severe dengue
The course of dengue illness
Febrile phase
● High-grade fever, 2–7 days

● facial flushing, skin erythema, body ache, myalgia, arthralgia,
  headache and N/V
● Indistinguishable between severe and non-severe dengue cases

● Monitoring for warning signs

● Mild hemorrhagic manifestations : petechiae and mucosal
  membrane bleeding (e.g. nose and gums)
● Liver often enlarged and tender after a few days of fever

● The earliest abnormality in CBC : progressive decrease in
  WBC
The course of dengue illness




    Dengue: Guidelines for diagnosis, treatment, prevention and control. WHO 2009
Critical phase
● Day 3–7 of illness

● Progressive leukopenia  rapid ↓platelet count plasma
  leakage

● Patients without ↑capillary permeability will improve
● Patients with ↑capillary permeability : worse, lose plasma
  volume

● The degree of increase above the baseline HCT reflects
  severity of plasma leakage

• Shock-WBC may increase in patients with severe bleeding
The course of dengue illness




    Dengue: Guidelines for diagnosis, treatment, prevention and control. WHO 2009
Recovery phase

● Gradual reabsorption of extravascular compartment fluid
  takes place in the following 48–72 hours
● Well-being improves, appetite returns, GI symptoms abate,
  hemodynamic status stabilizes and diuresis ensues
● Rash : “isles of white in the sea of red” Some may
  experience generalized pruritus
● Hct stabilizes or lower due to the dilutional effect of
  reabsorbed fluid
● WBC usually rise soon after defervescence but the recovery
  of platelet count is typically later than that of WBC
Febrile, critical and recovery phases in
                       dengue

Febrile phase           Dehydration; high fever may cause
                        neurological disturbances and febrile
                        seizures in young children

Critical phase          Shock from plasma leakage; severe
                        hemorrhage; organ impairment

Recovery phase          Hypervolemia (only if iv fluid therapy
                        has been excessive and/or
                        has extended into this period)
Severe dengue
● Fever of 2–7 days plus any of the following
   Evidence of plasma leakage :
      high or progressively rising Hct
      pleural effusions or ascites
      circulatory compromise or shock (tachycardia, cold and clammy
       extremities, capillary refill time > 3 seconds, weak or undetectable
       pulse, narrow PP or, in late shock, unrecordable BP)
   Significant bleeding
   Altered level of consciousness (lethargy or restlessness, coma,
    convulsions)
   Severe GI involvement (persistent vomiting, increasing or intense
    abdominal pain, jaundice)
   Severe organ impairment (acute liver failure, ARF, encephalopathy or
    encephalitis, or other unusual manifestations, cardiomyopathy)
Diagnosis of Dengue Infection
● Antibody detection
   Hemagglutination Inhibition (HAI)
   ELISA (IgG/IgM)
   Rapid test (IgG/IgM)
● Antigen detection
   NS1 & E/M antigen
● RNA detection
   PCR
● Viral isolation
Diagnosis
      •   Approximate time-line of primary and
          secondary dengue virus infections and
          the diagnostic methods that can be used
          to detect infection
Interpretation of dengue diagnostic tests
Primary Infection

● NS1 antigen : Day 1 after onset of fever and up to day 9
● IgM antibody :
  Day 5 of infection, sometimes as early as Day 3
  IgM levels : peak in 2 weeks, followed by a 2 week rapid
   decay
  Undetectable 2 to 3 months after infection
● Low levels of IgG are detected in the early convalescent
  phase, not during the acute phase
Secondary Infection

● NS1 antigen : day 1 after onset of fever and up to day 9

● IgM response is more varied

● Usually preceded by IgG and appears quite late during the
  febrile phase
● Minority of patients will show no detectable levels of IgM

● May not be produced until 20 days after onset of infection

● High levels of IgG are detectable during the acute phase

● Persist for 30-40 days then decline to levels found in primary
  or past infection
Atypical neurological manifestations
              of dengue
● Neurologic abnormalities : uncommon during dengue
  fever
● DHF, encephalopathy is well recognized, from
  several factors
  cerebral anoxia
  cerebral edema
  cerebral hemorrhage
  hyponatremia
  toxicity secondary to liver failure
● Studies in southeast Asia, encephalopathy associated
  with classic DF can occur in up to half of the cases
Atypical gastrointestinal
           manifestations of dengue
• Hepatitis
    Hepatomegaly, jaundice and raised aminotransferase levels
     (AST>ALT)
    caused by the dengue virus and ⁄or Hypoxia and tissue ischemia
     in cases of shock
• Fulminant hepatic failure
    Severe hepatic dysfunction (ALT and AST >10x normal) was
    seen with DHF associated with spontaneous bleeding tendencies
    tends to occur more often in DHF or DSS compared to classic
    dengue infections
• Acalculous cholecystitis
• Acute pancreatitis
Atypical cardiovascular manifestations
           of dengue fever
● uncommon
● Cardiac rhythm disorders :
  atrioventricular blocks
  atrial fibrillation
  sinus node dysfunction
  ectopic ventricular beats
● Most are asymptomatic, benign self limiting course with
  resolution of infection
● Attributed to viral myocarditis
Atypical respiratory manifestations of
                  dengue
● ARDS
● Pulmonary hemorrhage : thrombocytopenia,
  changes in vascular permeability, platelet
  dysfunction
Dengue myositis

● Dengue fever : break bone fever, severe muscle, joint
  and bone pain
● Acute benign myositis : elevated SGOT, SGPT, and
  CPK
● Dengue virus infection may also cause persisting,
  severe, myositis for weeks
Lymphoreticular complications of
              dengue
● Dengue virus antigen is found predominantly in cells
  of the spleen, thymus and lymph nodes
● DHF, lymphadenopathy is observed in half of the
  cases
● Splenomegaly is rarely observed
● Splenic rupture and lymph node infarction in DHF
  are rare
Management of dengue infection
A stepwise approach to the
        management of dengue
Step I. Overall assessment
 History : symptoms, past medical and family history
 Physical examination : full physical and mental assessment
 Investigation : routine laboratory and dengue-specific
laboratory

Step II. Diagnosis, assessment of disease phase and severity

Step III. Management
 Disease notification
 Management decisions. Depending on the clinical
manifestations and other circumstances, patients may:
– be sent home (Group A);
– be referred for in-hospital management (Group B);
– require emergency treatment and urgent referral (Group C).
Dengue with who guidelines
Groups A-Patients who are sent
            home
• Encourage plenty of oral fluids

• Inform about the warning signs

• Paracetamol for high fever. Never aspirin,ibuprofen or
  other NSAIDS
Admission criteria
Group B-In Patient Hospital
      Management
Algorithm for fluid management in compensated shock
                 Compensated shock (SBP maintained but has signs of reduced perfusion)

                         Fluid resuscitation with isotonic crystalloid 5–10 ml/kg/hr over 1 hour

                                                 Improvement
                                                                                                             NO
       YES
                                                                                    Check HCT

IV crystalloid 5–7 ml/kg/hr for 1–2                            HCT↑ or high                                HCT↓
hours, then:
   reduce to 3–5 ml/kg/hr for 2–4 hours;                 Administer 2nd bolus of fluid             Consider significant
   reduce to 2–3 ml/kg/hr for 2–4 hours.                 10–20 ml/kg/hr for 1 hour                 occult/overt bleed
                                                                                                   Initiate transfusion
If patient continues to improve, fluid can be                     Improvement                     with fresh whole
further reduced.                                                                                   blood

Monitor HCT 6–8 hourly.
                                                             YES                   NO
If the patient is not stable, act according
to HCT levels:
                                                       If patient improves,
   if HCT ↑, consider bolus fluid administration
                                                       reduce to 7–10 ml/kg/hr
or increase fluid administration;
                                                       for 1–2 hours
   if HCT ↓, consider transfusion with fresh
                                                       Then reduce further
whole transfusion.

Stop at 48 hours.
Algorithm for fluid management in hypotensive shock
     Hypotensive shock Fluid resuscitation with 20 ml/kg isotonic crystalloid or colloid over 15 minutes.
                            Try to obtain a HCT level before fluid resuscitation

                                                   Improvement
                  YES                                                                           NO

                                                                                            Review 1st HCT
Crystalloid/colloid 10 ml/kg/hr for 1 hour,                                                                        HCT↓
then continue with:                                                HCT↑ or high
   IV crystalloid 5–7 ml/kg/hr for 1– 2 hours;       Administer 2nd bolus fluid (colloid)            Consider significant
   reduce to 3–5 ml/kg/hr for 2–4 hours;             10–20 ml/kg over ½-1 hour                       occult/overt bleed
   reduce to 2–3 ml/kg/hr for 2–4 hours.                                                             Initiate transfusion with
                                                                   Improvement                       fresh whole blood
If patient continues to improve, fluid can be
further reduced.
                                                             YES                     NO
Monitor HCT 6-hourly.                                                        Repeat 2nd HCT

If the patient is not stable, act according
                                                             HCT↑ or high                             HCT↓
to HCT levels:
   if HCT ↑, consider bolus fluid administration
                                                     Administer 3rd bolus fluid (colloid)
or increase fluid administration;
                                                     10–20 ml/kg over 1 hour
   if HCT ↓, consider transfusion with fresh
whole transfusion.
                                                             Improvement
Stop at 48 hours.
                                                       YES                   NO
                                                                                       Repeat 3rd HCT
Treatment of hemorrhagic
               complications
● Mucosal bleeding :
   if patient remains stable with fluid resuscitation/replacement,
   considered as minor


● Bleeding improves rapidly during recovery phase

● Patients with profound thrombocytopenia :
   strict bed rest and protect from trauma
   not give i.m injections (avoid hematoma)
   prophylactic platelet transfusions for severe thrombocytopaenia in
   hemodynamically stable patients not shown to be effective and not
   necessary
Management of Dengue Infection

● No hemorrhagic manifestations and patient is well-
  hydrated:
   home treatment


● Hemorrhagic manifestations or hydration borderline:
   outpatient observation center or hospitalization


● Warning signs (even without profound shock) or
  DSS:
   hospitalize
Treatment of Dengue Fever

● Fluids
● Rest
● Antipyretics (avoid aspirin and NSAIDs)
● Monitor blood pressure, hematocrit, platelet
  count, level of consciousness
Dengue with who guidelines

Más contenido relacionado

La actualidad más candente

La actualidad más candente (20)

Dengue in Children
Dengue in ChildrenDengue in Children
Dengue in Children
 
Dengue Hemorrhagic Fever and DSS
Dengue Hemorrhagic Fever and DSSDengue Hemorrhagic Fever and DSS
Dengue Hemorrhagic Fever and DSS
 
dengue diagnosis and management
dengue diagnosis and managementdengue diagnosis and management
dengue diagnosis and management
 
Dengue fever
Dengue feverDengue fever
Dengue fever
 
Fever
FeverFever
Fever
 
Dengue Fever(2),09
Dengue Fever(2),09Dengue Fever(2),09
Dengue Fever(2),09
 
National Dengue Management Guideline for Bangladesh
National Dengue Management Guideline for BangladeshNational Dengue Management Guideline for Bangladesh
National Dengue Management Guideline for Bangladesh
 
Viral Hemorrhagic Fevers
Viral Hemorrhagic FeversViral Hemorrhagic Fevers
Viral Hemorrhagic Fevers
 
Dengue
DengueDengue
Dengue
 
Dengue epidemiology& case management
Dengue epidemiology& case managementDengue epidemiology& case management
Dengue epidemiology& case management
 
Dengue fever
Dengue feverDengue fever
Dengue fever
 
Pertussis (whooping cough)
Pertussis (whooping cough)Pertussis (whooping cough)
Pertussis (whooping cough)
 
Lab diagnosis of Dengue
Lab diagnosis of DengueLab diagnosis of Dengue
Lab diagnosis of Dengue
 
Dengue fever
Dengue feverDengue fever
Dengue fever
 
Fever in children
Fever in childrenFever in children
Fever in children
 
5 Hemorrhagic Fever With Renal Syndrome
5 Hemorrhagic Fever With Renal Syndrome5 Hemorrhagic Fever With Renal Syndrome
5 Hemorrhagic Fever With Renal Syndrome
 
Dengue haemorrhagic fever diagnosis & management
Dengue haemorrhagic fever diagnosis & managementDengue haemorrhagic fever diagnosis & management
Dengue haemorrhagic fever diagnosis & management
 
DENGUE IN CHILDREN
DENGUE IN CHILDRENDENGUE IN CHILDREN
DENGUE IN CHILDREN
 
Dengue fever presentation
Dengue fever presentationDengue fever presentation
Dengue fever presentation
 
Dengue fever Epidemiology - pathogenesis - symptoms - diagnosis - Management ...
Dengue fever Epidemiology - pathogenesis - symptoms - diagnosis - Management ...Dengue fever Epidemiology - pathogenesis - symptoms - diagnosis - Management ...
Dengue fever Epidemiology - pathogenesis - symptoms - diagnosis - Management ...
 

Destacado

Destacado (6)

Dengue fever slide
Dengue fever slideDengue fever slide
Dengue fever slide
 
DENGUE FEVER
DENGUE FEVERDENGUE FEVER
DENGUE FEVER
 
Accerlerated hypertension
Accerlerated hypertensionAccerlerated hypertension
Accerlerated hypertension
 
Dengue ppt
Dengue pptDengue ppt
Dengue ppt
 
Dengue ppt
Dengue pptDengue ppt
Dengue ppt
 
Dengue Fever Power Point
Dengue Fever Power PointDengue Fever Power Point
Dengue Fever Power Point
 

Similar a Dengue with who guidelines

The dengue syndrome_Vighnesh D
The dengue syndrome_Vighnesh DThe dengue syndrome_Vighnesh D
The dengue syndrome_Vighnesh DVighnesh D
 
Dengue diagnosis and management Bangladesh perspective
Dengue diagnosis and management Bangladesh perspective Dengue diagnosis and management Bangladesh perspective
Dengue diagnosis and management Bangladesh perspective DRIMTIAZ3
 
DengueManagementinED.pptx
DengueManagementinED.pptxDengueManagementinED.pptx
DengueManagementinED.pptxFahimMazlan1
 
CHD 4B Revised Dengue Case Management.ppt
CHD 4B Revised Dengue Case Management.pptCHD 4B Revised Dengue Case Management.ppt
CHD 4B Revised Dengue Case Management.pptTineanigra
 
Dengue management
Dengue managementDengue management
Dengue managementSarosh Khan
 
Dengue Fever - Brief Description, Diagnosis and Management
Dengue Fever - Brief Description, Diagnosis and ManagementDengue Fever - Brief Description, Diagnosis and Management
Dengue Fever - Brief Description, Diagnosis and ManagementDr Divyanshu Martand
 
Dengue Syndrome by Dr Faisal Ahmed Abbas
Dengue Syndrome by Dr Faisal Ahmed AbbasDengue Syndrome by Dr Faisal Ahmed Abbas
Dengue Syndrome by Dr Faisal Ahmed AbbasHarendra Singh
 
Dengue, DHF, DSS, PREVENTION, MANAGEMENT, TREATMENT
Dengue, DHF, DSS, PREVENTION, MANAGEMENT, TREATMENTDengue, DHF, DSS, PREVENTION, MANAGEMENT, TREATMENT
Dengue, DHF, DSS, PREVENTION, MANAGEMENT, TREATMENTDr-Hem Shah
 
Dengue, DHF, DSS, prevention, prognosis and its management
Dengue, DHF, DSS, prevention, prognosis and its managementDengue, DHF, DSS, prevention, prognosis and its management
Dengue, DHF, DSS, prevention, prognosis and its managementDr. Hem Shah
 
Dengue&dhf information for health care practitioners 2009
Dengue&dhf information for health care practitioners 2009Dengue&dhf information for health care practitioners 2009
Dengue&dhf information for health care practitioners 2009Tonzaaton Oozaa
 

Similar a Dengue with who guidelines (20)

The dengue syndrome_Vighnesh D
The dengue syndrome_Vighnesh DThe dengue syndrome_Vighnesh D
The dengue syndrome_Vighnesh D
 
DENGUE.pptx
DENGUE.pptxDENGUE.pptx
DENGUE.pptx
 
Dengue 1
Dengue 1Dengue 1
Dengue 1
 
9.dengue seminar
9.dengue seminar9.dengue seminar
9.dengue seminar
 
Dengue
DengueDengue
Dengue
 
Dengue diagnosis and management Bangladesh perspective
Dengue diagnosis and management Bangladesh perspective Dengue diagnosis and management Bangladesh perspective
Dengue diagnosis and management Bangladesh perspective
 
Dengue fever
Dengue feverDengue fever
Dengue fever
 
dengue virus.pptx
dengue virus.pptxdengue virus.pptx
dengue virus.pptx
 
DengueManagementinED.pptx
DengueManagementinED.pptxDengueManagementinED.pptx
DengueManagementinED.pptx
 
CHD 4B Revised Dengue Case Management.ppt
CHD 4B Revised Dengue Case Management.pptCHD 4B Revised Dengue Case Management.ppt
CHD 4B Revised Dengue Case Management.ppt
 
Dengue management
Dengue managementDengue management
Dengue management
 
Dengue virus
Dengue virusDengue virus
Dengue virus
 
Dengue, dengue hemorrhagic fever, dengue shock syndrome
Dengue, dengue hemorrhagic fever, dengue shock syndromeDengue, dengue hemorrhagic fever, dengue shock syndrome
Dengue, dengue hemorrhagic fever, dengue shock syndrome
 
Dengue Fever - Brief Description, Diagnosis and Management
Dengue Fever - Brief Description, Diagnosis and ManagementDengue Fever - Brief Description, Diagnosis and Management
Dengue Fever - Brief Description, Diagnosis and Management
 
Dengue Syndrome by Dr Faisal Ahmed Abbas
Dengue Syndrome by Dr Faisal Ahmed AbbasDengue Syndrome by Dr Faisal Ahmed Abbas
Dengue Syndrome by Dr Faisal Ahmed Abbas
 
Dengue Fever.ppt
Dengue Fever.pptDengue Fever.ppt
Dengue Fever.ppt
 
Dengue-CBD.pdf
Dengue-CBD.pdfDengue-CBD.pdf
Dengue-CBD.pdf
 
Dengue, DHF, DSS, PREVENTION, MANAGEMENT, TREATMENT
Dengue, DHF, DSS, PREVENTION, MANAGEMENT, TREATMENTDengue, DHF, DSS, PREVENTION, MANAGEMENT, TREATMENT
Dengue, DHF, DSS, PREVENTION, MANAGEMENT, TREATMENT
 
Dengue, DHF, DSS, prevention, prognosis and its management
Dengue, DHF, DSS, prevention, prognosis and its managementDengue, DHF, DSS, prevention, prognosis and its management
Dengue, DHF, DSS, prevention, prognosis and its management
 
Dengue&dhf information for health care practitioners 2009
Dengue&dhf information for health care practitioners 2009Dengue&dhf information for health care practitioners 2009
Dengue&dhf information for health care practitioners 2009
 

Más de Singaram_Paed

Approach to childhood rickets
Approach to childhood ricketsApproach to childhood rickets
Approach to childhood ricketsSingaram_Paed
 
Approach arthritis in childhood
Approach arthritis in childhoodApproach arthritis in childhood
Approach arthritis in childhoodSingaram_Paed
 
Megaloblastic anemia in childhood
Megaloblastic anemia in childhoodMegaloblastic anemia in childhood
Megaloblastic anemia in childhoodSingaram_Paed
 
Breast feeding and complimentary feeds
Breast feeding and complimentary feedsBreast feeding and complimentary feeds
Breast feeding and complimentary feedsSingaram_Paed
 
Terminology mechanical ventilation
Terminology mechanical ventilationTerminology mechanical ventilation
Terminology mechanical ventilationSingaram_Paed
 
Upper GI bleeding & portal hypertension in Children
Upper GI bleeding & portal hypertension in ChildrenUpper GI bleeding & portal hypertension in Children
Upper GI bleeding & portal hypertension in ChildrenSingaram_Paed
 
Iron deficiency anemia
Iron deficiency anemiaIron deficiency anemia
Iron deficiency anemiaSingaram_Paed
 
Intracranial hemorrhage newborn
Intracranial hemorrhage newbornIntracranial hemorrhage newborn
Intracranial hemorrhage newbornSingaram_Paed
 
Pyrexia of unknown origin
Pyrexia of unknown originPyrexia of unknown origin
Pyrexia of unknown originSingaram_Paed
 
Approach to a child with failure to thrive
Approach to a child with failure to thriveApproach to a child with failure to thrive
Approach to a child with failure to thriveSingaram_Paed
 
Rickettsial infections
Rickettsial infectionsRickettsial infections
Rickettsial infectionsSingaram_Paed
 

Más de Singaram_Paed (12)

Approach to childhood rickets
Approach to childhood ricketsApproach to childhood rickets
Approach to childhood rickets
 
Approach arthritis in childhood
Approach arthritis in childhoodApproach arthritis in childhood
Approach arthritis in childhood
 
Megaloblastic anemia in childhood
Megaloblastic anemia in childhoodMegaloblastic anemia in childhood
Megaloblastic anemia in childhood
 
Breast feeding and complimentary feeds
Breast feeding and complimentary feedsBreast feeding and complimentary feeds
Breast feeding and complimentary feeds
 
Terminology mechanical ventilation
Terminology mechanical ventilationTerminology mechanical ventilation
Terminology mechanical ventilation
 
Approach myoclonus
Approach myoclonusApproach myoclonus
Approach myoclonus
 
Upper GI bleeding & portal hypertension in Children
Upper GI bleeding & portal hypertension in ChildrenUpper GI bleeding & portal hypertension in Children
Upper GI bleeding & portal hypertension in Children
 
Iron deficiency anemia
Iron deficiency anemiaIron deficiency anemia
Iron deficiency anemia
 
Intracranial hemorrhage newborn
Intracranial hemorrhage newbornIntracranial hemorrhage newborn
Intracranial hemorrhage newborn
 
Pyrexia of unknown origin
Pyrexia of unknown originPyrexia of unknown origin
Pyrexia of unknown origin
 
Approach to a child with failure to thrive
Approach to a child with failure to thriveApproach to a child with failure to thrive
Approach to a child with failure to thrive
 
Rickettsial infections
Rickettsial infectionsRickettsial infections
Rickettsial infections
 

Último

Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...bkling
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
General_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_WellbeingGeneral_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_WellbeingAnonymous
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
Pregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfPregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfMedicoseAcademics
 
concept of total quality management (TQM).
concept of total quality management (TQM).concept of total quality management (TQM).
concept of total quality management (TQM).kishan singh tomar
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?Ryan Addison
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 

Último (20)

Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
General_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_WellbeingGeneral_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_Wellbeing
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
Pregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfPregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdf
 
concept of total quality management (TQM).
concept of total quality management (TQM).concept of total quality management (TQM).
concept of total quality management (TQM).
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 

Dengue with who guidelines

  • 1. Dengue infection ReviseD Who guiDelines 2009
  • 2. Dengue viral infection ● The most rapidly spreading mosquito-borne viral disease in the world ● Dengue virus : 4 serotypes : DEN1, DEN2,DEN3, and DEN4 Family Flaviviridae Genus Flavivirus Single stranded RNA virus ● “Asian” genotypes of DEN-2 and DEN-3 : frequently associated with severe disease accompanying secondary dengue infections
  • 4. Average annual number of DF and DHF cases reported to WHO, and of countries reporting dengue, 1955–2007
  • 5. Dengue Virus Infection ● Immunity : long lasting in same serotype, partial and transient to other serotypes ● Primary infection, secondary infection ● Greater risk of serious symptoms in secondary infection • Plasma leakage distinguishes dengue fever from dengue hemorrhagic fever • Plasma leakage,hemoconcentration and abnormalities in homeostasis characterize severe dengue
  • 6. Dengue Virus Infection: Clinical Syndromes ● Undifferentiated fever ● Dengue fever: fever, headache, muscle pain, nausea/vomiting, rash ● DHF ● DSS Gr I, II Plasma leakage Gr III, IV
  • 7. Definition of Dengue Hemorrhagic Fever 4 necessary criteria: • Fever, or recent history of acute fever • Hemorrhagic manifestations ● Low platelet count (100,000/mm3 or less) ● Objective evidence of “leaky capillaries”  elevated hematocrit (20% or more over baseline)  pleural or other effusions  Fall in hematocrit >20% after I.V Fluids
  • 8. Definition of Dengue Shock Syndrone 4 criteria for DHF ● Evidence of circulatory failure manifested indirectly by all of the following:  Rapid and weak pulse  Narrow pulse pressure (< 20 mm Hg) OR hypotension for age  Cold, clammy skin and altered mental status ● Frank shock is direct evidence of circulatory failure
  • 9. WHO classification ● Undifferentiated fever ● Dengue fever (DF) ● Dengue haemorrhagic fever (DHF) 4 severity grades grades III and IV : dengue shock syndrome (DSS) ● Currently the classification into DF/DHF/DSS continues to be widely used
  • 11. ● patients with non-severe dengue patients with warning signs patients without warning signs ● “dengue is one disease entity with different clinical presentations and often with unpredictable clinical evolution and outcome”
  • 13. Vectors ● Aedes aegypti Stegomyia aegypti (formerly Aedes aegypti)
  • 14. Dengue ● incubation period of 4-10 days ● wide spectrum of illness (most, asymptomatic or subclinical) ● Primary infection : induce lifelong protective immunity to the infecting serotype ● Individuals suffering an infection are protected from clinical illness with a different serotype within 2-3 months of the primary infection ● no long-term cross-protective immunity
  • 15. Risk factors (determine the severity of disease and secondary infection) ● Age ● Ethnicity ● Possibly chronic diseases (bronchial asthma, sickle cell anemia and DM) ● Young children (less able to compensate for capillary leakage and are consequently at greater risk of dengue shock) ● Secondary heterotypic infection as risk factor for severe dengue
  • 16. The course of dengue illness
  • 17. Febrile phase ● High-grade fever, 2–7 days ● facial flushing, skin erythema, body ache, myalgia, arthralgia, headache and N/V ● Indistinguishable between severe and non-severe dengue cases ● Monitoring for warning signs ● Mild hemorrhagic manifestations : petechiae and mucosal membrane bleeding (e.g. nose and gums) ● Liver often enlarged and tender after a few days of fever ● The earliest abnormality in CBC : progressive decrease in WBC
  • 18. The course of dengue illness Dengue: Guidelines for diagnosis, treatment, prevention and control. WHO 2009
  • 19. Critical phase ● Day 3–7 of illness ● Progressive leukopenia  rapid ↓platelet count plasma leakage ● Patients without ↑capillary permeability will improve ● Patients with ↑capillary permeability : worse, lose plasma volume ● The degree of increase above the baseline HCT reflects severity of plasma leakage • Shock-WBC may increase in patients with severe bleeding
  • 20. The course of dengue illness Dengue: Guidelines for diagnosis, treatment, prevention and control. WHO 2009
  • 21. Recovery phase ● Gradual reabsorption of extravascular compartment fluid takes place in the following 48–72 hours ● Well-being improves, appetite returns, GI symptoms abate, hemodynamic status stabilizes and diuresis ensues ● Rash : “isles of white in the sea of red” Some may experience generalized pruritus ● Hct stabilizes or lower due to the dilutional effect of reabsorbed fluid ● WBC usually rise soon after defervescence but the recovery of platelet count is typically later than that of WBC
  • 22. Febrile, critical and recovery phases in dengue Febrile phase Dehydration; high fever may cause neurological disturbances and febrile seizures in young children Critical phase Shock from plasma leakage; severe hemorrhage; organ impairment Recovery phase Hypervolemia (only if iv fluid therapy has been excessive and/or has extended into this period)
  • 23. Severe dengue ● Fever of 2–7 days plus any of the following  Evidence of plasma leakage :  high or progressively rising Hct  pleural effusions or ascites  circulatory compromise or shock (tachycardia, cold and clammy extremities, capillary refill time > 3 seconds, weak or undetectable pulse, narrow PP or, in late shock, unrecordable BP)  Significant bleeding  Altered level of consciousness (lethargy or restlessness, coma, convulsions)  Severe GI involvement (persistent vomiting, increasing or intense abdominal pain, jaundice)  Severe organ impairment (acute liver failure, ARF, encephalopathy or encephalitis, or other unusual manifestations, cardiomyopathy)
  • 24. Diagnosis of Dengue Infection ● Antibody detection  Hemagglutination Inhibition (HAI)  ELISA (IgG/IgM)  Rapid test (IgG/IgM) ● Antigen detection  NS1 & E/M antigen ● RNA detection  PCR ● Viral isolation
  • 25. Diagnosis • Approximate time-line of primary and secondary dengue virus infections and the diagnostic methods that can be used to detect infection
  • 26. Interpretation of dengue diagnostic tests
  • 27. Primary Infection ● NS1 antigen : Day 1 after onset of fever and up to day 9 ● IgM antibody : Day 5 of infection, sometimes as early as Day 3 IgM levels : peak in 2 weeks, followed by a 2 week rapid decay Undetectable 2 to 3 months after infection ● Low levels of IgG are detected in the early convalescent phase, not during the acute phase
  • 28. Secondary Infection ● NS1 antigen : day 1 after onset of fever and up to day 9 ● IgM response is more varied ● Usually preceded by IgG and appears quite late during the febrile phase ● Minority of patients will show no detectable levels of IgM ● May not be produced until 20 days after onset of infection ● High levels of IgG are detectable during the acute phase ● Persist for 30-40 days then decline to levels found in primary or past infection
  • 29. Atypical neurological manifestations of dengue ● Neurologic abnormalities : uncommon during dengue fever ● DHF, encephalopathy is well recognized, from several factors cerebral anoxia cerebral edema cerebral hemorrhage hyponatremia toxicity secondary to liver failure ● Studies in southeast Asia, encephalopathy associated with classic DF can occur in up to half of the cases
  • 30. Atypical gastrointestinal manifestations of dengue • Hepatitis  Hepatomegaly, jaundice and raised aminotransferase levels (AST>ALT)  caused by the dengue virus and ⁄or Hypoxia and tissue ischemia in cases of shock • Fulminant hepatic failure  Severe hepatic dysfunction (ALT and AST >10x normal) was seen with DHF associated with spontaneous bleeding tendencies  tends to occur more often in DHF or DSS compared to classic dengue infections • Acalculous cholecystitis • Acute pancreatitis
  • 31. Atypical cardiovascular manifestations of dengue fever ● uncommon ● Cardiac rhythm disorders : atrioventricular blocks atrial fibrillation sinus node dysfunction ectopic ventricular beats ● Most are asymptomatic, benign self limiting course with resolution of infection ● Attributed to viral myocarditis
  • 32. Atypical respiratory manifestations of dengue ● ARDS ● Pulmonary hemorrhage : thrombocytopenia, changes in vascular permeability, platelet dysfunction
  • 33. Dengue myositis ● Dengue fever : break bone fever, severe muscle, joint and bone pain ● Acute benign myositis : elevated SGOT, SGPT, and CPK ● Dengue virus infection may also cause persisting, severe, myositis for weeks
  • 34. Lymphoreticular complications of dengue ● Dengue virus antigen is found predominantly in cells of the spleen, thymus and lymph nodes ● DHF, lymphadenopathy is observed in half of the cases ● Splenomegaly is rarely observed ● Splenic rupture and lymph node infarction in DHF are rare
  • 35. Management of dengue infection
  • 36. A stepwise approach to the management of dengue Step I. Overall assessment  History : symptoms, past medical and family history  Physical examination : full physical and mental assessment  Investigation : routine laboratory and dengue-specific laboratory Step II. Diagnosis, assessment of disease phase and severity Step III. Management  Disease notification  Management decisions. Depending on the clinical manifestations and other circumstances, patients may: – be sent home (Group A); – be referred for in-hospital management (Group B); – require emergency treatment and urgent referral (Group C).
  • 38. Groups A-Patients who are sent home • Encourage plenty of oral fluids • Inform about the warning signs • Paracetamol for high fever. Never aspirin,ibuprofen or other NSAIDS
  • 40. Group B-In Patient Hospital Management
  • 41. Algorithm for fluid management in compensated shock Compensated shock (SBP maintained but has signs of reduced perfusion) Fluid resuscitation with isotonic crystalloid 5–10 ml/kg/hr over 1 hour Improvement NO YES Check HCT IV crystalloid 5–7 ml/kg/hr for 1–2 HCT↑ or high HCT↓ hours, then: reduce to 3–5 ml/kg/hr for 2–4 hours; Administer 2nd bolus of fluid Consider significant reduce to 2–3 ml/kg/hr for 2–4 hours. 10–20 ml/kg/hr for 1 hour occult/overt bleed Initiate transfusion If patient continues to improve, fluid can be Improvement with fresh whole further reduced. blood Monitor HCT 6–8 hourly. YES NO If the patient is not stable, act according to HCT levels: If patient improves, if HCT ↑, consider bolus fluid administration reduce to 7–10 ml/kg/hr or increase fluid administration; for 1–2 hours if HCT ↓, consider transfusion with fresh Then reduce further whole transfusion. Stop at 48 hours.
  • 42. Algorithm for fluid management in hypotensive shock Hypotensive shock Fluid resuscitation with 20 ml/kg isotonic crystalloid or colloid over 15 minutes. Try to obtain a HCT level before fluid resuscitation Improvement YES NO Review 1st HCT Crystalloid/colloid 10 ml/kg/hr for 1 hour, HCT↓ then continue with: HCT↑ or high IV crystalloid 5–7 ml/kg/hr for 1– 2 hours; Administer 2nd bolus fluid (colloid) Consider significant reduce to 3–5 ml/kg/hr for 2–4 hours; 10–20 ml/kg over ½-1 hour occult/overt bleed reduce to 2–3 ml/kg/hr for 2–4 hours. Initiate transfusion with Improvement fresh whole blood If patient continues to improve, fluid can be further reduced. YES NO Monitor HCT 6-hourly. Repeat 2nd HCT If the patient is not stable, act according HCT↑ or high HCT↓ to HCT levels: if HCT ↑, consider bolus fluid administration Administer 3rd bolus fluid (colloid) or increase fluid administration; 10–20 ml/kg over 1 hour if HCT ↓, consider transfusion with fresh whole transfusion. Improvement Stop at 48 hours. YES NO Repeat 3rd HCT
  • 43. Treatment of hemorrhagic complications ● Mucosal bleeding :  if patient remains stable with fluid resuscitation/replacement, considered as minor ● Bleeding improves rapidly during recovery phase ● Patients with profound thrombocytopenia :  strict bed rest and protect from trauma  not give i.m injections (avoid hematoma)  prophylactic platelet transfusions for severe thrombocytopaenia in hemodynamically stable patients not shown to be effective and not necessary
  • 44. Management of Dengue Infection ● No hemorrhagic manifestations and patient is well- hydrated:  home treatment ● Hemorrhagic manifestations or hydration borderline:  outpatient observation center or hospitalization ● Warning signs (even without profound shock) or DSS:  hospitalize
  • 45. Treatment of Dengue Fever ● Fluids ● Rest ● Antipyretics (avoid aspirin and NSAIDs) ● Monitor blood pressure, hematocrit, platelet count, level of consciousness

Notas del editor

  1. - Grade I     มีไข้และมีอาการร่วมอื่นๆแต่ไม่จำเพาะ แต่เมื่อทำ tourniquet test จะให้ผล positive - Grade II     อาการเหมือน grade I แต่ที่เพิ่มเติมคือ พบเลือดออกเป็นจุดเลือดใต้ผิวหนัง - Grade III     ระบบไหลเวียนโลหิตเริ่มล้มเหลวเกิดอาการช็อค ชีพจรเร็ว เบา pulse pressure แคบ ความดันโลหิตต่ำ ริมฝีปากเขียว ตัวเย็น กระสับกระส่าย - Grade IV     แสดงอาการช็อครุนแรง ความดันโลหิตและชีพจรวัดไม่ได้  
  2. 21
  3. 22
  4. - Grade I     มีไข้และมีอาการร่วมอื่นๆแต่ไม่จำเพาะ แต่เมื่อทำ tourniquet test จะให้ผล positive - Grade II     อาการเหมือน grade I แต่ที่เพิ่มเติมคือ พบเลือดออกเป็นจุดเลือดใต้ผิวหนัง - Grade III     ระบบไหลเวียนโลหิตเริ่มล้มเหลวเกิดอาการช็อค ชีพจรเร็ว เบา pulse pressure แคบ ความดันโลหิตต่ำ ริมฝีปากเขียว ตัวเย็น กระสับกระส่าย - Grade IV     แสดงอาการช็อครุนแรง ความดันโลหิตและชีพจรวัดไม่ได้
  5. dengue infection is defined as primary if IgM/IgG OD ratio &gt; 1.2 (using pt’s sera at 1/100 dilution) or 1.4 (using pt’s sera at 1/20 dilutions) secondary if ratio &lt;1.2 or 1.4 Ratios : vary between lab